An Open-label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution, 0.02% in Healthy Volunteers

Trial Profile

An Open-label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution, 0.02% in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2015

At a glance

  • Drugs Netarsudil (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Pharmacokinetics
  • Sponsors Aerie Pharmaceuticals
  • Most Recent Events

    • 01 May 2015 Results published in the American Journal of Ophthalmology.
    • 04 Dec 2013 New source identified and integrated: ClinicalTrials.gov record NCT01997879 .
    • 04 Dec 2013 New source identified and integrated: ClinicalTrials.gov record NCT01997879 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top